https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Characterizing Foxp3⁺ and Foxp3⁻ T cells in the homeostatic state and after allo-activation: resting CD4⁺Foxp3⁺ Tregs have molecular characteristics of activated T cells https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54659 Wed 10 Apr 2024 09:45:50 AEST ]]> Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19941 Tue 18 Aug 2015 11:14:17 AEST ]]> Functional significance and risk factors for lymphocele formation after renal transplantation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48956 Tue 18 Apr 2023 15:35:05 AEST ]]> Assessment of restored kidney transplantation including the use of wider criteria for accepting renal donors after cancer excision. https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49387 60 years old and accepted onto the National Organ Matching Service. This RKT Group was divided into donor renal cancers ≤30 mm and >30–≤50 mm. Adverse event profiles for RKT recipients were compared with 22 standard live donor recipients using logistic regression analyses. Recipient and transplant survivals for RKT were compared with 2050 controls from Australian New Zealand Dialysis Transplant Registry using Cox regression models. To increase statistical power for survival analyses, data from 25 RKT recipients from Princess Alexandra Hospital, Brisbane were added, thus creating 48 RKT recipients.Results: There were no significant differences in mortality, transplant failure nor AEs between the 2 cancer Groups. RKT increased the risks of Adverse event profiles (odds ratio: 6.48 [2.92–15.44]; P < 0.001). RKT reduced mortality risk by 30% (hazard ratio [HR]: 0.70 [0.36–1.07]; P = 0.299) compared with those continuing on the transplant list who may or may not be transplanted. RKT significantly reduced mortality risk for those remaining on dialysis (HR: 2.86 [1.43–5.72]; P = 0.003). Transplant survival for RKT was reduced compared with control deceased donor (HR: 0.42 [0.21–0.83]; P = 0.013) and live donor transplants (HR: 0.33 [0.02–0.86]; P =0.023).Conclusions:The use of larger carefully selected cancer-resected kidneys for transplantation appears safe and effective. RKT confers a possible survival advantage compared with waiting for transplantation, an increased survival compared with those remaining on dialysis but reduced transplant survival.]]> Fri 12 May 2023 14:27:13 AEST ]]>